AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12502940
Drug: Moisturizing agent
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing agent usage
Trial: 1958439
Drug: Betahistine 72
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 72 mg three times daily
Trial: 1958439
Drug: Prochlorperazine 5
RxNorm normalized name: prochlorperazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 5 mg three times daily
Trial: 28735928
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg (active reference)
Trial: 25720711
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy and rehabilitation training
Trial: 25720711
Drug: Conventional therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy, rehabilitation training and botulinum toxin type A injection
Trial: 25720711
Drug: AFO plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFO plus conventional therapy and rehabilitation training
Trial: 22081618
Drug: Mate tea
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mate tea consumption (330 mL, 3 times a day for 60 days)
Trial: 19843808
Drug: Naloxone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone group (34 mL lidocaine 1.5% with 100 ng naloxone)
Trial: 19843808
Drug: Naloxone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone + Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl and 100 ng naloxone)
Trial: 19843808
Drug: Fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl)
Trial: 19843808
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (34 mL lidocaine 1.5% with isotonic saline)
Trial: 11517140
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg intravenously at the end of surgery and 8 mg in PCA morphine solution
Trial: 11517140
Drug: Morphine via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine via PCA syringe
Trial: 2973300
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with rt-PA immediately followed by transluminal coronary angioplasty (group 1, n = 183)
Trial: 28647541
Drug: Response tailored
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response tailored duration of dual sofosbuvir/daclatasvir treatment (8 or 12 weeks based on vRVR)
Trial: 28647541
Drug: Fixed 12
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 12 weeks duration of dual sofosbuvir/daclatasvir treatment
Trial: 25280085
Drug: Fostamatinib (R788)
RxNorm normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib (R788) 100 mg BID
Trial: 23459567
Drug: Alemtuzumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (12 mg or 24 mg)
Trial: 16871129
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 20 mg/day
Trial: 16871129
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 40 mg/day
Trial: 16871129
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 60 mg/day
Trial: 16871129
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR (all doses)
Trial: 14668006
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of mifepristone every 2 weeks for 24 weeks
Trial: 9395376
Drug: Interferon-alpha (IFN-alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 6 months
Trial: 9395376
Drug: Interferon-alpha (IFN-alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 12 months
Trial: 8236464
Drug: Proguanil daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil daily (PROG)
Trial: 8236464
Drug: Chloroquine once
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine once weekly (CQ)
Trial: 8236464
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chloroquine and Proguanil (CQ+PROG)
Trial: 29540410
Drug: Patella mobilisation
RxNorm normalized name: Blatella germanica
DrugBank: Blatella germanica (DB10418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patella mobilisation therapy (PMT) with three manual mobilisation sessions and home-based vastus medialis oblique muscle exercise at 2-month intervals
Trial: 22568118
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus bBTi (4 weekly 1-hour individual sessions)
Trial: 17233546
Drug: Osteoporosis medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoporosis medications (e.g., Bisphosphonates)
Trial: 17233546
Drug: Strategies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies to increase adherence (e.g., reducing administration frequency, monitoring patients, providing instructions)
Trial: 17233546
Drug: Non-adherence factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherence factors (e.g., adverse effects, pain, uncertainty about BMD test results)
Trial: 240481
Drug: Practolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (200 mg twice daily)
Trial: 31810418
Drug: Quadrivalent influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent influenza vaccine (QIV) in thiomersal-containing multi-dose vial (MDV) format
Trial: 30467686
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Clopidogrel + Cilostazol
Trial: 25925203
Drug: IV amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amino acid therapy (up to 100 g daily)
Trial: 23948391
Drug: overnight storage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: overnight storage with alkaline peroxide-based cleansing tablet
Trial: 15451900
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (premeal inhaled insulin plus a bedtime dose of Ultralente)
Trial: 15451900
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (at least two daily injections of mixed regular/NPH insulin)
Trial: 9229982
Drug: Minimal-flow anaesthesia
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-flow anaesthesia with desflurane (0.5 l/min fresh gas flow)
Trial: 9229982
Drug: Low-flow anaesthesia
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow anaesthesia with desflurane (1.0 l/min fresh gas flow)
Trial: 9229982
Drug: High-flow phase
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow phase with desflurane (4.4 l/min fresh gas flow)
Trial: 3524549
Drug: Prostaglandin F2
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2 alpha in Tylose gel
Trial: 24453500
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) treatment at 42°C for 120 seconds to the dorsal root ganglion (DRG)
Trial: 12190752
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.2‐0.4 micro g.kg‐1.min‐1)
Trial: 12190752
Drug: Fentanyl bolus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl bolus (3 micro g.kg‐1) + propofol infusion (2 mg.kg‐1.h‐1)
Trial: 6211167
Drug: Atropine methonitrate
RxNorm normalized name: Atropine methonitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine methonitrate (2 mg) as a wet aerosol
Trial: 6211167
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide and terbutaline
Trial: 6211167
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide and terbutaline combination
Trial: 23813620
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg single dose
Trial: 23813620
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg single dose
Trial: 23813620
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg single dose
Trial: 23813620
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg multiple doses
Trial: 17081163
Drug: Nitazoxanide 500
RxNorm normalized name: nitazoxanide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500 mg twice daily for 3 days
Trial: 15579757
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 or 8 mg/d) for 26 weeks
Trial: 9422013
Drug: Medical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatments (n = 94)
Trial: 8101550
Drug: HIV-immune plasma
RxNorm normalized name: IMMUNE GLOBULIN PLASMA BOVINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-immune plasma (250 mL every 4 weeks)
Trial: 8101550
Drug: HIV antibody-negative
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV antibody-negative plasma (250 mL every 4 weeks)
Trial: 3552925
Drug: Prednisolone therapy
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone therapy (28-day course)
Trial: 30141288
Drug: EMG guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG guided point injection at Renying (ST 9), administered three times a week for 2 weeks, in addition to conventional drugs and rehabilitation training.
Trial: 30141288
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs combined with rehabilitation training, administered once daily for 2 weeks.
Trial: 23512320
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing intervention using smart scales and e-mail
Trial: 18219456
Drug: Gout prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gout prescription I
Trial: 18219456
Drug: Gout prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gout prescription II
Trial: 18219456
Drug: Gout prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gout prescription III
Trial: 12823646
Drug: Warfarin 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 1.25 mg + Aspirin 75 mg daily (W/A)
Trial: 11905682
Drug: Radical prostatectomy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical prostatectomy, radical radiotherapy, and monitoring with treatment if required.
Trial: 1464336
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of metoprolol
Trial: 31486253
Drug: Low-dose tramadol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tramadol (0.5 mg/kg)
Trial: 31486253
Drug: Meperidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.5 mg/kg and 0.75 mg/kg)
Trial: 31486253
Drug: Fentanyl (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.5 mcg/kg and 0.75 mcg/kg)
Trial: 29502373
Drug: Postoperative precision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative precision nutrition treatment
Trial: 29502373
Drug: Traditional postoperative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional postoperative nutrition treatment
Trial: 25251377
Drug: Zeaxanthin only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zeaxanthin only (20 mg/day; n=29)
Trial: 25251377
Drug: Mixed formulation
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed formulation (26 mg/day zeaxanthin, 8 mg/day lutein, and 190 mg/day mixed omega‐3 fatty acids; n=25)
Trial: 23158830
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care for the prevention and treatment of DM2 currently provided in Osakidetza
Trial: 21061788
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159)
Trial: 12691318
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Trial: 17922895
Drug: r-hGH administered
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH administered by cool.click 2
Trial: 17922895
Drug: r-hGH administered
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH administered by needle and syringe
Trial: 16320942
Drug: Test sustained-release
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test sustained-release indapamide formulation (3 mg)
Trial: 16320942
Drug: Reference sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference sustained-release indapamide formulation (3 mg)
Trial: 11880565
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (ferrous sulfate 300 mg/tablet)
Trial: 11880565
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (ferrous sulfate 300 mg/tablet)
Trial: 7649495
Drug: Allopurinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200 mg during induction of anesthesia and 100 mg after starting extracorporeal circulation)
Trial: 2669552
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with dog or cat extract (n = 14), subcutaneous injections with alum-adsorbed depot extract (Alutard-SQ), maintenance dose of 100,000 SQ-U or maximum tolerated dose.
Trial: 2669552
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy (n = 13).
Trial: 2669552
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with dog or cat extract (n = 14).
Trial: 31146544
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg monthly (initial dosage)
Trial: 28582403
Drug: Cholecalcipherol (300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalcipherol (300,000 IU) combined with standard treatment (methotrexate and glucocorticoids)
Trial: 28582403
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (methotrexate and glucocorticoids) without cholecalcipherol
Trial: 23855643
Drug: Antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic regimen (pre- and post-operative)
Trial: 23454858
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment of the medial malleolus
Trial: 16764619
Drug: Laparoscopic ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic ovarian drilling (LOD) plus 1700 mg per day of metformin for 6 months
Trial: 2758733
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of cimetidine (300 mg every 6 hours)
Trial: 2758733
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cimetidine (37.5 mg per hour with a priming dose of 300 mg for 15 minutes)
Trial: 28776062
Drug: Mindfulness practice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness practice (20-min sessions weekly for one academic semester)
Trial: 25871786
Drug: CASUS® group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CASUS® group (using online cases for preparation)
Trial: 30502311
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no noninvasive ventilation)
Trial: 28859383
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium alginate (10 mL of Gaviscon Advance)
Trial: 28859383
Drug: Water (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (10 mL)
Trial: 25847503
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet-rich gel (APG) plus standard treatment
Trial: 25847503
Drug: Topical APG
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical APG application
Trial: 24080677
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy
Trial: 21422207
Drug: Voriconazole 300
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 300 mg
Trial: 21422207
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg
Trial: 12909380
Drug: CC-CPR training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-CPR training (n=36)
Trial: 10877011
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg single oral dose in healthy controls
Trial: 10877011
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg single oral dose in malaria patients
Trial: 10877011
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg single oral dose in both groups
Trial: 10437215
Drug: Electro-acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture and routine treatment (Group 1, n = 29)
Trial: 10437215
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment alone (Group 2, n = 30)
Trial: 30549489
Drug: NAC +
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC + aspirin (1,000 mg each)
Trial: 30549489
Drug: NAC (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC (1,000 mg)
Trial: 20398037
Drug: MK-0429 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0429 200 mg b.i.d.
Trial: 20398037
Drug: MK-0429 1600
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0429 1600 mg b.i.d.
Trial: 23343466
Drug: Pre-exposure cream
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exposure cream
Trial: 23343466
Drug: Post-exposure cream
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-exposure cream
Trial: 23343466
Drug: Pre-exposure cream
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exposure cream + Post-exposure cream